- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Robert Berenson, MD, FACP, Discusses How to Better Inform Providers on Quality Measures
Robert Berenson, MD, FACP, Institue Fellow, Health Policy Center, Urban Institute, states that the development of new care delivery models will not happen overnight. There is time before expectations are put into specific quality metrics and regulations for models such as patient-centered medical homes and accountable care organizations.
Robert Berenson, MD, FACP, Institue Fellow, Health Policy Center, Urban Institute, states that the development of new care delivery models will not happen overnight. There is time before expectations are put into specific quality metrics and regulations for models such as patient-centered medical homes (PCMHs) and accountable care organizations (ACOs).
Dr. Berenson also thinks that quality measures at the individual level are ill advised. He says that there will be great progress when quality measures are used for PCMHs and ACOs.
This video was taken on September 10 at AHIP's 2012 Medicare and Medicaid Conference in Washington, DC.
Dr Kathryn Lindley Explains the Importance of Cardio-Obstetrics in Fellowship Programs
December 5th 2023Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, talks about why it’s important to incorporate cardio-obstetrics training into cardiovascular disease fellowship programs.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
HMO and EPO Insurance Plans More Likely to Promote Use of Biosimilars
November 21st 2023Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Read More
